IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that dosing has been initiated in a Phase I study of the drug candidate IRL757.
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that dosing has been initiated in a Phase I study of the drug candidate IRL757.